4D Molecular Therapeutics
Dhaval B. Desai is an accomplished pharmaceutical executive with extensive experience in leadership roles within the biotechnology and pharmaceutical industries. Currently serving as Chief Development Officer at 4D Molecular Therapeutics since August 2024, Dhaval previously held the position of Senior Vice-President & Chief Development Officer at Iveric Bio from August 2020 to August 2024, along with the role of Chief of Staff. Prior to Iveric Bio, Dhaval was VP & Medical Unit Head in Ophthalmology at Novartis from June 2018 to August 2020. Dhaval's career includes significant positions at Aerpio Therapeutics, ThromboGenics, Onyx Pharmaceuticals, Sanofi, and Integrated Communications, demonstrating a strong background in medical affairs and strategy. Academic credentials include a Doctor of Pharmacy (PharmD) degree from Rutgers University, obtained from 1995 to 2001.
This person is not in any teams
This person is not in any offices
4D Molecular Therapeutics
6 followers
4D Molecular Therapeutics designs develop and commercialize transformative gene therapy products for serious unmet medical conditions.